Houston health orgs lost $58M in canceled, stalled NIH grants, new report shows

research cuts

The Science & Community Impacts Mapping Project identified 37 cancelled or frozen NIH grants for Houston institutions. Photo via Unsplash.

Seven institutions in the Houston area have lost nearly $60 million in grants from the National Institutes of Health (NIH) that were aimed at funding health research.

The Science & Community Impacts Mapping Project identified 37 cancelled or frozen NIH grants worth $58.7 million that were awarded to seven Houston-area institutions. The University of Texas Medical Branch at Galveston suffered the biggest loss — five grants totaling nearly $44.8 million.

The Harvard University T.H. Chan School of Public Health reported in May that over the previous several months across the U.S., the federal government had terminated roughly 2,100 NIH research grants worth around $9.5 billion.

In August, the U.S. Supreme Court derailed researchers’ efforts to reinstate almost $2 billion in research grants issued by NIH, according to Nature.com.

“Make no mistake: This was a decision critical to the future of the nation, and the Supreme Court made the wrong choice. History will look upon these mass National Institutes of Health (NIH) research grant terminations with shame,” the American Association of Medical Colleges said in a statement. “The Court has turned a blind eye to this grievous attack on science and medicine, and we call upon Congress to take action to restore the rule of law at NIH.”

Texas health researchers rely heavily on NIH grants and contracts. During the federal government’s 2024 budget year, NIH awarded $1.9 billion in grants and contracts that directly supported 30,553 jobs and more than $6.1 billion in economic activity in Texas, according to the United for Medical Research coalition.

Here’s a rundown of the cancelled and frozen NIH grants in the Houston area.

  • University of Texas Medical Branch at Galveston: Five cancelled or frozen grants, totalling approximately $44.8 million in funding lost.
  • Baylor College of Medicine: 17 grants cancelled or frozen, totalling approximately $8 million in funding lost
  • University of Houston. Five cancelled or frozen grants, totalling approximately $3.7 million in funding lost
  • University of Texas Health Science Center Houston: Five grants cancelled or frozen, totaling approximately $1.1 million in funding lost.
  • University of Texas MD Anderson Cancer Center: Two grants cancelled or frozen, totalling $831,581 in funding
  • Rice University. Two grants cancelled or frozen, totaling $254,645 in funding lost
  • Prairie View A&M University: One grant cancelled or frozen, totalling $31,771 in funding lost
From Your Site Articles
MD Anderson is teaming up with TOPPAN Holdings on cutting-edge organoid tech to help match cancer patients with the most effective treatments. Photo via Getty Images.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

MD Anderson Cancer Center received $3 million to establish a new genomics research hub. Photo by F. Carter Smith/Courtesy of MD Anderson

Houston hospital to establish genomics research hub as part of CPRIT's $60M round of grants

coming soon

Houston’s University of Texas MD Anderson Cancer Center will create a genomics research hub thanks to a nearly $3 million award from the Cancer Prevention and Research Institute of Texas, or CPRIT.

“This groundbreaking facility will have a profound impact on cancer research, and improving the diagnosis and treatment of cancer patients in Texas,” says CPRIT.

CPRIT gave the monetary award to Nicholas Navin, a professor at MD Anderson and at the biomedical sciences school within the University of Texas Health Science Center at Houston (UTHealth Houston).

The new facility will specialize in advanced spatial genomics, which creates a three-dimensional “atlas” that’s been dubbed “the Google Map of the human body,” according to CPRIT.

“Spatial genomics is an exciting new field that allows cancer researchers to directly connect the images of cells and their tissue structures with genomic data while preserving the spatial context,” CPRIT explains. “This provides the researchers with the ability to see exactly where distinct types of cells are located within a tumor, and determine the genes and proteins they are expressing.”

Until recently, most genomic technologies such as DNA and RNA sequencing required scientists to “grind up” tumor tissues to extract molecules for analysis, according to CPRIT.

“This process means losing the complex composition of the different cell types and their spatial arrangement within the tumor, which makes it difficult to understand the complex environment of cancer cells,” the institute adds.

MD Anderson’s new genomics hub will feature tissue processing, slide imaging, spatial genomics technologies, and spatial data analysis methods for cancer researchers within the Texas Medical Center and around the state.

In other CPRIT funding news, three local medical institutions received a total of $8 million for recruitment of four cancer researchers.

MD Anderson received half of the $8 million from CPRIT. The money will go toward bring aboard:

  • Hojong Yoon. Yoon, recipient of a $2 million scholar recruitment award, is a postdoctoral student at the Cambridge, Massachusetts-based Broad Institute. The institute, affiliated with Harvard University and MIT, is a research organization. Yoon’s research focuses on targeted cancer therapy.
  • Marianna Trakala. Trakala, recipient of a $2 million scholar recruitment award, is a postdoctoral researcher at MIT’s Koch Institute for Integrative Cancer Research. She is studying how small conditional RNA (scRNA) causes a response that triggers activation of the immune system and elimination of cancer cells from tissue.

The Baylor College of Medicine and the University of Texas Health Science Center at Houston (UTHealth Houston) each received one $2 million scholar recruitment award:

  • Louai Labanieh, a postdoctoral researcher at Stanford University’s Parker Institute for Cancer Immunotherapy, is joining the Baylor College of Medicine. Labanieh’s research involves engineering next-generation cells to improve cancer immunotherapy.
  • Yanjun Sun, a neuroscientist who is a postdoctoral scholar at Stanford, is joining UTHealth Houston.

In all, CPRIT recently doled out more than $60 million for cancer-fighting efforts around the state. Aside from the Baylor College of Medicine, MD Anderson, and UTHealth Houston, Rice University and Texas Southern University received CPRIT funding.

“By supporting the vital core facilities that researchers need, funding groundbreaking research, and deepening the bench of clinical trial investigators, CPRIT is fulfilling the promise central to our mission: We are helping Texans conquer cancer,” says Kristen Doyle, CEO of CPRIT.

MD Anderson broke ground on a 600,000 square-foot building that is specifically designed to enable great minds to meet with the goal of conquering cancer. Photo courtesy of MD Anderson

Houston-based, cancer-fighting organization breaks ground on new collaborative building

ready to rise

Houston is where medical researchers and clinicians come together. And it’s getting easier for that to happen thanks to an innovative new facility from The University of Texas MD Anderson Cancer Center.

On September 20, the world-class institution broke ground on a 600,000 square-foot building that is specifically designed to enable great minds to meet with the goal of conquering cancer.

Construction on the seven-story structure, known as South Campus Research Building 5 (SCRB5), is supported by a $668 million institutional grant. The facility is expected to be completed in 2026. Designed by Elkus Manfredi Architects, it will include both high-tech research rooms and public spaces that include a restaurant, conference center and spaces for lectures. A landscaped park is designed by Mikyoung Kim Design.

“The construction of our visionary new research building marks the beginning of our next chapter in Making Cancer History,” Peter WT Pisters, M.D., president of MD Anderson, says in a press release. “With input from hundreds of MD Anderson teammates, we have carefully designed this building and our research campus to foster collaboration, to stimulate creativity and to fuel breakthroughs that will improve the lives of patients here and around the globe.”

SCRB5 is located at 1920 Spanish Trail and is considered an extension of upcoming Helix Park, Texas Medical Center’s 5 million square-foot research campus. Both are specifically designed to create seamless collaborations between scientists and clinicians, where water cooler chat can lead to world-changing discoveries. MD Anderson has already announced that the building will be home to a number of strategic research programs, including the James P. Allison Institute.

The new construction isn’t just notable for the discoveries that will be made there. In itself, SCRB5 will be an exceptionally sustainable and efficient building, with surrounding green spots and connecting pathways that will serve as inspiration for all who work there. This only makes sense for MD Anderson, which invested $1.1 billion in funding in the last fiscal year. In the same year, the institution had more projects funded by the National Cancer Institute than any other.

Rendering courtesy of MD Anderson

Six Houston inventors have been recognized with the highest professional distinction for inventors within academia. Photo via Pexels

6 Houston-area inventors named fellows in prestigious program

best in class

The National Academy of Inventors has announced its annual set of NAI Fellows — and six Houstonians make the list of the 164 honorees from 116 research institutions worldwide.

The NAI Fellows Program honors academic inventors "who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and the welfare of society," according to a news release. The appointment is the highest professional distinction for inventors within academia.

The six Houstonians on the list join a group that hold more than 48,000 U.S. patents, which have generated over 13,000 licensed technologies and companies, and created more than one million jobs, per the release. Additionally, $3 trillion in revenue has been generated based on NAI Fellow discoveries.

These are the scientists from Houston organizations:

    • Zhiqiang An, University of Texas Health Science Center at Houston: An is the director of the Texas Therapeutics Institute, a drug discovery program operated by the John P. and Kathrine G. McGovern Medical School at Houston. He's also a professor of molecular medicine and holder of the Robert A. Welch Distinguished University Chair in Chemistry at UTHealth.
    • Alex Ignatiev, University of Houston: Ignatiev served as director of two NASA-supported research and technology development centers at the University of Houston and as Lillie Cranz and Hugh Roy Cullen Professor of Physics, Chemistry, and Electrical and Computer Engineering.
    • David Jaffray, University of Texas MD Anderson Cancer Center: Jaffray was appointed MD Anderson's first-ever chief technology and digital officer in 2019. He oversees MD Anderson’s Information Services division and Information Security department and is a professor of Radiation Physics with a joint appointment in Imaging Physics.
    • Pei-Yong Shi,The University of Texas Medical Branch: Pei-Yong Shi is a professor and John Sealy Distinguished Chair in Innovations in Molecular Biology Department of Biochemistry & Molecular Biology;. He's also the Vice Chair for Innovation and Commercialization.
    • Ganesh Thakur, University of Houston: Thakur is a pioneer in carbon capture, utilization and storage and has a patent on forecasting performance of water injection and enhanced oil recovery. His team is continuing to push the research envelope for CCUS employing world-class lab research, simulation, machine learning and artificial intelligence.
    • Darren Woodside, Texas Heart Institute: Woodside is the Vice President for Research and Director of the Flow Cytometry and Imaging Core at the Texas Heart Institute. His research centers around the role that cell adhesion plays in cardiovascular and autoimmune diseases, and the development of novel means to identify and treat these diseases.
    Ten other Texas-based innovators made the list, including:
    • Sanjay Banerjee, The University of Texas at Austin
    • Thomas Boland, The University of Texas at El Paso
    • Joan Brennecke, The University of Texas at Austin
    • Gerard Cote, Texas A&M University
    • Ananth Dodabalapur, The University of Texas at Austin
    • Holloway (Holly) H. Frost Jr., The University of Texas at Arlington
    • James E. Hubbard, Texas A&M University
    • Yi Lu, University of Texas at Austin
    • Samuel Prien, Texas Tech University
    • Earl E. Swartzlander Jr., The University of Texas at Austin
    This year's class will be inducted at the Fellows Induction Ceremony at the 11th Annual Meeting of the National Academy of Inventors in June in Phoenix, Arizona.

    "The caliber of this year's class of NAI Fellows is outstanding. Each of these individuals are highly-regarded in their respective fields," says Paul R. Sanberg, president of NAI's board of directors, in the release. "The breadth and scope of their discovery is truly staggering. I'm excited not only see their work continue, but also to see their knowledge influence a new era of science, technology, and innovation worldwide."

    Ad Placement 300x100
    Ad Placement 300x600

    CultureMap Emails are Awesome

    Property Showcase

    UH scores $18M NIH grant for chronic disease research

    research funding

    The University of Houston has received a coveted $18.8 million grant from the National Institutes of Health to launch a program to address the root causes of chronic disease.

    Only 22 institutions nationwide receive this NIH award, and the 5-year process aligns with the newly established UH Health’s mission to expand healthcare innovations in Texas and beyond. The initiative will be housed in the UH Population Health department.

    "This generous funding allows us to directly confront the root causes of chronic illness that place a heavy burden on so many families," Dr. Jonathan McCullers, vice president for health affairs at UH, said in a news release. "With the recent launch of UH Health, we have an unprecedented opportunity to translate scientific discovery into healthier outcomes for our communities by bringing together experts from across the university to improve health where it matters most.”

    Through the program, UH researchers from different areas of expertise will work together to address the challenges of chronic illness by looking at biological, social and behavioral factors.

    According to the university, chronic diseases like heart disease, diabetes, strokes and others are the leading cause of illness, disability and death in the U.S. They account for 90 percent of the nation’s $5.3 trillion in annual healthcare spending.

    Bettina Beech, chief of population health and translational science at UH, serves as principal investigator for the program.

    “Chronic disease management largely happens during the 8,700 hours each year that people are not visiting their healthcare provider,” Beech added in the news release. “While healthcare is indispensable, it only accounts for 20 percent of how health is created — genetics accounts for another 10 percent, and the other 70 percent is determined by behavior, social conditions and environment.”

    With the funds from the grant, UH will also be able to expand research infrastructure, add to community partnerships, support complementary research, and invest in early-career investigators, according to the news release. UH also aims to develop solutions that could help ease the economic burden of chronic disease.

    Report: Where Texas ranks among best and worst states to live in 2026

    Texas Talk

    After earning its worst-ever ranking last year, Texas has improved slightly on an evaluation of the best states to live, but it's still at the bottom of the pack.

    Each year, WalletHub's analysts compare all 50 states using 51 livability metrics to measure their affordability, economy, education and health, quality of life, and safety. Factors that were weighed include the cost of living, homeownership rates, population and income growth rates, wealth gaps, public school system quality, road quality, crime rates, and many others.

    The Lone Star State landed at No. 36 in 2026, making it the 15th worth state to live right now. That's on par with its 2024 ranking, and it's a two-spot improvement over its 2025 performance.

    While Texas residents can brag about living in a state with the No. 1 highest number of restaurants per capita and the 7th best quality of life in the country, that's about it. Texas earned middling-to-poor scores among the four remaining livability rankings: safety (No. 33), affordability (No. 35), economy (No. 37), and education and health (No. 40).

    Here's how Texas fared in other nationwide rankings in the study:

    • No. 27 – Income Growth
    • No. 30 – Housing Costs
    • No. 39 – Percentage of Population in Poverty
    • No. 42 – Percentage of Adults in Fair or Poor Health
    • No. 46 – Homeownership Rate
    • No. 49 – Percentage of Population Aged 25 and Older with a High School Diploma or Higher
    • No. 48 – Average Weekly Work Hours
    • No. 50 – Percentage of Insured Population

    Texas has a lot of work to do to improve its livability for all of its residents, but especially for women, according to several other 2026 WalletHub studies. Texas is the fourth-worst state for women, the ninth-worst state for working mothers, and the seventh-worst place to have a baby based on limited access to maternal and pediatric healthcare.

    At the very bottom of the report is New Mexico, ranking 50th overall, with Louisiana (No. 49), Mississippi (No. 48), Alaska (No. 47), and Arkansas (No. 46) rounding out the bottom five.

    After holding on as the No. 1 best state to live for a few years in a row, Massachusetts now ranks No. 4 and was overtaken by Idaho (No. 1), New Jersey (No. 2), and Wisconsin (No. 3). New Hampshire rounds out the top five best states to live.

    WalletHub's top 10 best states to live in 2026 are:

    • No. 1 – Idaho
    • No. 2 – New Jersey
    • No. 3 – Wisconsin
    • No. 4 – Massachusetts
    • No. 5 – New Hampshire
    • No. 6 – Wyoming
    • No. 7 – Utah
    • No. 8 – Minnesota
    • No. 9 – Pennsylvania
    • No. 10 – Florida
    ---

    This article originally appeared on CultureMap.com.

    6 exciting Houston startup raises to know from July 2026

    fresh funding

    Houston startups carried the fundraising momentum of Q1 and Q2 into July with several significant seed funding, Series A and Series B rounds.

    From geothermal leaders to medtech innovators, these six Houston companies raised more than a quarter billion dollars last month alone, according to reporting by InnovationMap and our sister site, EnergyCapitalHTX.com.

    Did we miss a funding round? Let us know by emailing innoeditor@innovationmap.com.

    Altillion

    Houston-based startup Altillion has secured $5 million in seed funding to accelerate the commercialization of its proprietary IRIS and ALIX technologies, which convert oilfield-produced water into valuable minerals, the company reported earlier this month.

    San Francisco-based EIC Rose Rock and Houston-based Flathead Forge led the round. Altillion says the funding will go toward pilot facilities and commercial deployments as the company looks to scale in the U.S. Continue reading.

    Buildforce

    The U.S. is grappling with a current shortage of 50,000 electricians, according to the National Electrical Contractors Association. Photo via Unsplash

    Houston-based Buildforce, which provides a tech-enabled staff platform geared toward electricians and electrical contractors, closed a $10 million Series A round led by Houston’s Saepio Capital last month.

    Other investors in the round include Blue Heron Capital, Revolution’s Rise of the Rest Seed Fund, S3 Ventures and Chicago Ventures.

    Buildforce says the funding will help fuel its national expansion and further development of its technology.

    The startup, founded in 2019, connects electricians with electrical contractors for commercial and industrial construction projects. Continue reading.

    Hephae Energy Technology Corp.

    The company develops ultra-high-temperature tools to withstand the heat of geothermal reservoirs. Photo via hephaeet.com

    Houston-area startup Hephae Energy Technology Corp. closed a $17.8 million Series A financing round last month to commercialize its geothermal technology.

    The round was co-led by Pennsylvania-based Susquehanna Sustainable Investments, which invests in early-stage climatech companies, and Copenhagen-based Underground Ventures, which focuses on geothermal energy startups. Alfa8, Baruch Future Ventures, Centaurus Capital LP, Elemental Impact, Exa Ventures, Future Ventures, Grantham Foundation for the Protection of the Environment, New System Ventures and True North Institute joined the round, along with existing Houston-based investor Nabors Industries. Hephae reports in a news release that the Series A round brings the company's total capital raised to $24.7 million. Continue reading.

    TYBR Health

    The company's B3 GEL System is designed to protect tendons, ligaments and muscles while they heal from orthopedic surgery. Photo via Unsplash

    Houston-based healthtech startup TYBR Health has raised a $30 million Series A round to scale its B3 GEL System, which helps protect tendons from scarring after surgery, the company announced last month.

    The round was led by Minneapolis-based Vensana Capital and Cleveland-based Mutual Capital Partners, with participation from Denver-based Neovate Capital Partners and existing investors, according to a news release from the company.

    TYBR Health said it plans to use the funding to broaden the B3 GEL System's clinical applications, expand commercialization and conduct studies to evaluate its ability to protect tissue and improve healing outcomes. Continue reading.

    Venus Aerospace 

    Venus Aerospace has secured funding from Mercury Fund, Lockheed Martin Ventures and others. Photo courtesy Venus Aerospace

    Houston-based Venus Aerospace closed a $91 million Series B round last month and plans to scale the production of its hypersonic engine.

    The round was led by Houston-based Mercury Fund with participation from Lockheed Martin Ventures, MESH, PEAK6, Draper Associates, Starboard Star Venture Capital, Green Sands Equity and other investors, according to a news release.

    The investment comes about a year after Venus completed the first U.S. flight test of its high-thrust rotating detonation rocket engine (RDRE). The engine is expected to enable vehicles to travel four to six times the speed of sound from a conventional runway and is about 15 percent more efficient than traditional alternatives, according to the company. Continue reading.

    Quaise Energy

    A rendering of a Quaise Energy geothermal plant. Rendering via quaise.com

    Houston-based Quaise Energy, a producer of utility-scale geothermal power, closed $134 million in a Series B round last month to advance its “superhot” geothermal power plant.

    Climate-focused San Francisco-based investment firm Prelude Ventures led the round, with participation from JERA Co., Japan’s largest power generation company, and Idemitsu Kosan, one of Japan’s largest energy companies. Nearly all existing investors, including cleantech-focused investment firm Safar Partners, participated in the round.

    The startup expects more equity and debt deals to close “imminently.” Quaise has raised $230 million since its founding in 2018. Continue reading.

    View All Listings